Bayer Links OTC User Fees To Exclusivity, Hisamitsu Pans General Concept
This article was originally published in The Pink Sheet
Executive Summary
Bayer HealthCare encourages FDA to grant periods of market exclusivity to firms charged user fees for monograph proposal, while Hisamitsu America questions FDA's basic rationale for why a fee is needed to improve the monograph system.